Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05138133 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
A Phase 3 study of Lupus Nephritis, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 359
- Enrollment target
- 20
- Study locations
NCT05138133 is a Phase 3 study of Lupus Nephritis that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 359 participants, above the 298-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT05138133, a Phase 3 study of Lupus Nephritis, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 359 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Anifrolumab
Study Locations (20)
Texas
- Research Site - Colleyville
- Research Site - Edinburg
- Research Site - El Paso
- Research Site - Houston
Other
- Research Site - CABA
- Research Site - Ciudad de Buenos Aires
- Research Site - La Plata
- Research Site - Rosario
California
- Research Site - La Palma
- Research Site - Los Angeles
- Research Site - Upland
New York
- Research Site - Manhasset
- Research Site - New York
Arizona
- Research Site - Glendale
Florida
- Research Site - Plantation
Georgia
- Research Site - Atlanta
Kentucky
- Research Site - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2028-12-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05138133
The ClinicalTrials.gov registry entry for NCT05138133 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 359 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 298-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (20% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lupus Nephritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05138133 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Texas, Other, California.
Frequently Asked Questions
What is clinical trial NCT05138133 about?
NCT05138133 is a clinical study titled "Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis". The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
What is the current status of trial NCT05138133?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 359 participants. The study started on 2022-02-15. Estimated completion is 2028-12-05.
What conditions does trial NCT05138133 study?
This clinical trial studies the following conditions: Lupus Nephritis.
What interventions are being tested in trial NCT05138133?
The interventions under investigation include: Placebo (DRUG), Anifrolumab (DRUG).
Who is sponsoring clinical trial NCT05138133?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05138133 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
COMPLETED · Phase 3
-
Aurinia Renal Response in Active Lupus With Voclosporin
COMPLETED · Phase 3
-
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
RECRUITING · Phase 2
-
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.